VANCOUVER, British Columbia — August 14, 2025 — Leads & Copy — Fifty1 AI Labs, Inc. (OTC: FITY) has announced the completion of a comprehensive study of Sickle Cell Disease (SCD). The study utilized a decade’s worth of real-world patient data to map disease progression and treatment outcomes. The research was funded by The Gates Foundation and conducted with scientists from the University of Pittsburgh School of Medicine and the Stellenbosch University Centre for Infectious Diseases in South Africa. Findings have been submitted to a hematology journal and will be presented in Senegal this September. The study serves as a catalyst for next-generation gene-based therapies and the repurposing of existing medicines.
Paul Arora, CEO of Fifty1 AI Labs, stated the study combines AI-driven analytics with world-class partnerships.
Investor Relations, Fifty 1 Labs, Inc., ir@fifty1labs.com, (877) 505-5006
Source: Fifty1 AI Labs, Inc.
